Natural Carbohydrate-based Vaccine Development

Natural Carbohydrate-based Vaccine Development

Carbohydrates are widely used in the development of vaccines and have made great progress. To promote customers' progress in carbohydrate-based vaccine development projects, CD BioGlyco is committed to providing comprehensive scientific services including vaccine design, manufacturing, and quality control.

Natural Carbohydrate-based Vaccine

Carbohydrates represent the most extensive class of biomolecules in nature. They play critical roles in immune system function and can be developed and utilized by the chemical community. Naturally derived glycans, such as cell surface polysaccharides from viruses, bacteria, and parasites, have become valuable antigenic targets for vaccine development.

Currently, the development of natural carbohydrate vaccines is relatively well established. The majority of licensed carbohydrate vaccines such as Salmonella typhi Vi, Haemophilus influenzae type b, Neisseria meningitides and Streptococcus pneumonia belong to this category, where carbohydrate antigens are isolated to form microbial cultures and then bound to carrier proteins. Although they have great efficacy against corresponding pathogens, there are several major problems in vaccine manufacturing, including complex purification procedures, heterogeneous components, impurities, uncontrollable and unproductive protein conjugation chemistry.

Fig. 1 Carbohydrate-based vaccines against a variety of diseases.Fig.1 Carbohydrate-based vaccines against a variety of diseases. (Hütter, 2015)

Our Solutions

Given the difficulties in the development of vaccines based on natural carbohydrates, CD BioGlyco mainly helps customers develop vaccines from the following aspects:

  • We have established a variety of purification and separation strategies for natural carbohydrates, such as capillary electrophoresis (CE), hydrophilic interaction chromatography (HILIC), and lectin enrichment.
  • We optimized the conjugation methods of glycans to immunogenic carrier proteins according to the functional groups available on the carrier proteins, to enhance the immunogenicity and efficacy of the vaccine. For example, conjugation via thioether formation between thiolated polysaccharide fragments and haloacylated carrier proteins ensures chemoselective couplings.
  • We select appropriate carrier proteins such as meningococcal outer membrane protein complex (OMPC), tetanus toxoid (TT) and keyhole limpet hemocyanin (KLH) to produce more efficacious glycoconjugate vaccines against diverse diseases.
  • We add suitable adjuvants such as aluminum phosphate or aluminum hydroxide to the vaccine to improve the immune response.

Advantages of Us

  • Professional research team
  • Advanced experimental platform
  • Years of successful experience
  • High quality and high purity products

CD BioGlyco has a dedicated research team composed of PhD-level scientists to help clients design and produce carbohydrate-based vaccines with high safety and efficacy. We will do our best to meet your research needs and provide the best service. If you need scientific assistance in vaccine development, please contact us directly and we will respond as soon as possible.


  1. Mettu, R.; et al. Synthetic carbohydrate-based vaccines: challenges and opportunities. Journal of Biomedical Science. 2020, 27(1):9.
  2. Hütter, J.; Lepenies, B. Carbohydrate-based vaccines: An overview. Springer New York. 2015, 1331:1-10.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.